| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
 Warning:  file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=12486206&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
 in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Mechanism of action of progesterone antagonists Leonhardt SA; Edwards DPExp Biol Med (Maywood)  2002[Dec]; 227 (11): 969-80The effects of progesterone on target tissues are mediated by progesterone  receptors (PRs), which belong to a family of nuclear receptors and function as  ligand-activated transcription factors to regulate the expression of specific  sets of target genes. Progesterone antagonists repress the biological actions of  progesterone by "actively" inhibiting PR activation. This work discusses the  first clinically used progesterone antagonist RU486 and closely related compounds  in terms of how these compounds inhibit progesterone action through  heterodimerization and competition for DNA binding and by the recruitment of  corepressors to promoters of target genes to repress transcription. We discuss  cellular factors that may influence the activity of these compounds, such as the  availability of coactivators and corepressors and the context of specific target  promoters in any given cell type. We also discuss steroidal and nonsteroidal  antagonist selectivity for PR versus other steroid hormone receptors and suggest  that it may be possible to develop tissue/cell specific modulators of PR.|Animals[MESH]|Hormone Antagonists/chemistry/*pharmacology[MESH]|Humans[MESH]|Mifepristone/pharmacology[MESH]|Progesterone/*antagonists & inhibitors/metabolism[MESH]|Receptors, Progesterone/*antagonists & inhibitors/chemistry/metabolism[MESH]|Signal Transduction[MESH]|Structure-Activity Relationship[MESH]
 |